Researchers develop data-driven methods for analyzing off-label drug use

by Molly Sharlach

(Medical Xpress)—Physicians often prescribe drugs for unapproved indications, but current methods of tracking these off-label uses are limited in scope.

Now, a study by researchers at the Stanford University School of Medicine describes a way to extract and sort valuable information about off-label uses from . The study's authors hope their findings will help to jump-start research into off-label uses that are promising, low-risk and low-cost, as well as flag potentially risky uses for further review.

Drugs prescribed for unapproved conditions, dosages or age groups account for 21 percent of all U.S. , according to a 2006 investigation published in the Archives of Internal Medicine. But only 27 percent of such uses are supported by robust science.

These statistics are not as alarming as they seem at first glance. The lengthy, costly drug-approval process makes a certain amount of off-label drug use inevitable. Off-label prescriptions are legal in most cases and can be an important source of innovation to accelerate new uses for drugs.

Nigam Shah, MBBS, PhD, assistant professor of medicine and senior author of the new study, believes better tracking and investigation of off-label use can help patients, physicians and regulators, but should also appeal to drug companies, who will benefit from new approved uses for their products. "Just as detection of abnormal spending is now a routine feature of credit card services, someday off-label use detection could be a routine part of health-care systems," Shah said.

The National Disease and Therapeutic Index relies on physician surveys to monitor off-label prescriptions, but the index is far from comprehensive. "We wanted to describe the whole universe of off-label use," said Kenneth Jung, a graduate student in biomedical informatics and the lead author of the study, published Feb. 19 in PLOS ONE.

For an extensive view of off-label drug use, Jung, Shah and their colleagues turned to STRIDE, the Stanford Translational Research Integrated Data Environment, which hosts a comprehensive warehouse of de-identified clinical notes, diagnoses and prescriptions for nearly 2 million patients treated since 1994 at Stanford Hospital & Clinics and Lucile Packard Children's Hospital Stanford.

The researchers built a program to run 9.5 million clinical notes from the STRIDE warehouse through the National Center for Biomedical Ontology Annotator, a tool funded by the NIH and designed to pick out names of drugs, diseases and from any text. After filtering their results and checking them for scientific support in the medical literature, they generated a final list of 403 off-label drug uses.

To prioritize these uses for further study, the researchers took into account the cost of each drug and its risk of causing adverse reactions. They used these two parameters to rank each drug use. "Then we placed them into good and bad buckets," Shah said. The "bad bucket" of high-cost, high-risk uses should raise red flags that prompt re-evaluation by physicians and regulators.

For indications in the "good bucket," Shah hopes to expedite tests in cell lines and mouse models. Positive results from these experiments may ultimately lead to clinical trials and new approvals. "The combination of and molecular evidence can make a stronger argument for agencies to fund clinical trials," said Shah, who is also a member of the Stanford Center for Biomedical Informatics Research.

Among the highest-risk drugs were immunosuppressants and anti-tumor agents. One of these was rituximab, an antibody that destroys the B cells of the immune system. It's approved for leukemia and lymphoma, but records show it's also used to treat purpura, a bleeding disorder that causes red or purple patches to appear on the skin. The study suggests that the high cost and considerable risk of severe reactions warrant further study before pursuing this use of the drug.

On the other hand, folic acid appeared to be a low-risk, low-cost treatment for a range of conditions, including mental depression, diarrhea and high cholesterol. Also known as vitamin B9, folic acid is found in some fruits, vegetables and whole grains, but patients often need a supplement to get enough to treat their condition. Also in the "good bucket" was the use of megestrol for patients with non-small cell lung carcinomas; the drug has traditionally been used to relieve symptoms in breast and endometrial cancer patients.

Jung was surprised by how many of the novel uses were predictable based on prior knowledge. "A lot of it actually made sense," he said. "We should have known about some of these uses already. This gives us confidence that the method we developed works."

However, this method cannot yet detect unapproved drug uses by age, sex, dosage or other contraindications. The researchers caution that some adverse reactions to drugs and co-morbidities—patient conditions unrelated to the prescribed drug—could have muddled their results. The team members said they will gain more confidence if they see similar outcomes when they apply the same methods to analyze electronic medical records from other hospitals.

add to favorites email to friend print save as pdf

Related Stories

Novel chemotherapies more often used on- than off-label

Feb 26, 2013

(HealthDay)—In contemporary practice, medical oncologists use novel anticancer agents on-label more often than off-label, according to a study published online Feb. 19 in the Journal of Clinical Oncology.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

8 hours ago

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments